美洛昔康市场报告：趋势、预测与竞争分析（至2031年）

由于类风湿性关节炎、骨关节炎、软组织发炎、创伤性疼痛和术后疼痛等领域的市场机会，全球美洛昔康市场前景广阔。预计2025年至2031年，全球美洛昔康市场将以8.8%的复合年增长率成长。推动该市场成长的关键因素包括慢性发炎性疾病盛行率的上升、对非类固醇消炎剂（NSAIDs）需求的成长以及人们对疼痛管理解决方案日益增长的认识。

• 根据 Lucintel 的预测，按类型和剂型分類的市场预计将在预测期内呈现最高的成长率。
• 根据应用情况来看，类风湿性关节炎预计将呈现最高的成长率。
• 从区域来看，预计亚太地区在预测期内将达到最高的成长率。

美洛昔康市场的新趋势

受对更精细化的患者照护的需求、对安全性的关注以及学名药的普及的推动，美洛昔康市场正在经历几个新兴趋势，反映出从传统口服片剂向更多样化和更有针对性的製剂的转变，以及对非阿片类镇痛解决方案的日益关注。

• 先进药物递送系统：一个显着的趋势是先进药物递送系统的开发，例如缓释片和外用凝胶。这些创新旨在透过减少给药频率和最大限度地减少全身副作用（尤其是胃肠道不适）来提高患者的依从性。这为长期管理关节炎等慢性疾病提供了更方便、更安全的治疗选择。
• 非鸦片类镇痛：一个关键趋势是将美洛昔康定位为治疗急性疼痛和术后疼痛的首选非鸦片类替代药物。新型速效製剂，包括静脉注射剂，已研发成功并核准，可在有效缓解疼痛的同时，避免阿片类药物相关的成瘾风险和副作用。这一趋势是对全球阿片类药物危机的直接回应。
• 非专利药的成长：非专利洛昔康的日益普及持续影响着市场格局。随着品牌药专利到期，许多生产商推出了价格更低的替代产品。这一趋势加剧了价格竞争，使更多患者能够获得美洛昔康，并扩大了其市场份额，尤其是在开发中国家。
• 联合疗法的进展：一种新兴趋势是基于美洛昔康的联合疗法的研究和开发，这种疗法将美洛昔康与其他活性成分结合，以同时针对疼痛和发炎的多个方面。此类策略旨在提高治疗效果，并提供更全面的治疗方法，特别适用于复杂的发炎性疾病。
• 扩展至兽医领域：美洛昔康在兽医领域的应用日益广泛，这是一个值得关注的趋势。美洛昔康是一种安全有效的非类固醇消炎剂（NSAID），可用于治疗伴侣动物和家畜的疼痛和发炎。随着人们对兽医领域的兴趣日益浓厚，这个应用领域为市场开闢了新的成长途径。

这些趋势正从根本上重塑美洛昔康市场，其应用范围已扩展至传统关节炎治疗之外，製剂也更加安全便捷，并透过学名药竞争提高了产品的可及性。市场正朝着更专业、针对特定应用的产品方向发展，以满足人类和动物医疗保健领域不断变化的需求。

美洛昔康市场近期趋势

在药物传递技术的创新以及对患者安全和便利性的重视的推动下，美洛昔康市场正在经历一系列关键发展，这些发展正在影响全球竞争格局和产品供应，旨在满足不断变化的医疗保健需求，尤其是在慢性疼痛管理和术后护理方面。

• 速效静脉製剂：一项重要进展是，一种用于治疗中重度急性疼痛的新型美洛昔康静脉製剂核准并上市。这种速效非鸦片类注射製剂为术后疼痛管理提供了重要的替代方案，并有助于减少鸦片类药物依赖。它的推出产生了显着影响，尤其是在医院环境中，快速起效至关重要。
• 缓释片：另一个重要进展是美洛昔康缓释性片的问世。这些製剂旨在每日一次给药，即可提供长达24小时的持续镇痛效果。这提高了患者的依从性，减少了给药频率，并最大限度地降低了胃肠道不适的风险，使其成为长期治疗慢性关节炎的更便捷选择。
• 学名药竞争加剧：随着关键专利的到期，市场学名药竞争日益激烈。这降低了美洛昔康的平均价格，使其更加经济实惠，并惠及更多患者。在对品牌药价格带来压力的同时，仿製药的出现也扩大了该药物的市场规模和整体使用率。
• 局部用凝胶：美洛昔康局部用凝胶的研发和上市是局部疼痛治疗领域的重大进步。它可以直接涂抹于患处，提供针对性缓解，同时减少全身用药及其相关副作用。这种剂型尤其适用于有特定关节骨关节炎等疾病的患者。
• 策略联盟与收购：製药公司正积极寻求策略联盟与收购，以拓展其美洛昔康产品系列与地理覆盖范围。与非专利生产商和专注于新型药物递送技术的公司的合作，正在加速市场成长，促进创新，并帮助企业获得竞争优势。

这些发展正透过产品多样化、提高病患安全性和便利性以及扩大市场进入，对美洛昔康市场产生重大影响。市场正从依赖传统口服片剂转向各种能够满足特定患者需求的製剂，从急性术后疼痛到慢性关节炎管理。

目录

第一章执行摘要

第二章 市场概览

• 背景和分类
• 供应链

第三章：市场趋势与预测分析

• 产业驱动因素与挑战
• PESTLE分析
• 专利分析
• 法规环境

第四章 全球美洛昔康市场（按类型划分）

• 吸引力分析：按类型
• 按成分
• 沿途
• 按剂型

5. 全球美洛昔康市场按应用领域划分

• 吸引力分析：依目的
• 类风湿性关节炎
• 骨关节炎
• 软组织炎症
• 创伤性疼痛
• 术后疼痛
• 其他的

第六章 区域分析

7. 北美美洛昔康市场

• 北美美洛昔康市场按类型划分
• 北美美洛昔康市场按应用领域划分
• 美国美洛昔康市场
• 墨西哥美洛昔康市场
• 加拿大美洛昔康市场

8. 欧洲美洛昔康市场

• 欧洲美洛昔康市场按类型划分
• 欧洲美洛昔康市场依应用分类
• 德国美洛昔康市场
• 法国美洛昔康市场
• 西班牙美洛昔康市场
• 义大利美洛昔康市场
• 英国美洛昔康市场

9. 亚太地区美洛昔康市场

• 亚太地区美洛昔康市场按类型划分
• 亚太地区美洛昔康市场按应用领域划分
• 日本美洛昔康市场
• 印度美洛昔康市场
• 中国美洛昔康市场
• 韩国美洛昔康市场
• 印尼美洛昔康市场

第十章 世界其他地区（ROW）美洛昔康市场

• 美洛昔康市场按类型划分
• 按应用分類的美洛昔康市场
• 中东美洛昔康市场
• 美洛昔康在南美洲的市场
• 非洲美洛昔康市场

第十一章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析
• 市占率分析

第十二章：机会与策略分析

• 价值链分析
• 成长机会分析
• 全球美洛昔康市场的新趋势
• 战略分析

第十三章：价值链中主要企业的概况

• 竞争分析
• Boehringer Ingelheim
• Baudax
• Perrigo
• Recro Pharma
• Iroko Pharma
• Zyla Life Sciences
• Axsome Therapeutics
• Orbis Biosciences
• Cellix Bio
• Ligand Pharma

第十四章附录

The future of the global meloxicam market looks promising with opportunities in the rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, and post-operative pain markets. The global meloxicam market is expected to grow with a CAGR of 8.8% from 2025 to 2031. The major drivers for this market are the increasing prevalence of chronic inflammatory diseases, the rising demand for non-steroidal anti-inflammatory drugs, and the growing awareness of pain management solutions.

• Lucintel forecasts that, within the type category, by dosage form is expected to witness the highest growth over the forecast period.
• Within the application category, rheumatoid arthritis is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Meloxicam Market

The meloxicam market is witnessing several emerging trends, which are driven by the need for enhanced patient care, a focus on safety, and the proliferation of generic alternatives. These trends reflect a shift from traditional oral tablets to more diverse and targeted formulations, as well as an increased focus on non-opioid pain management solutions.

• Advanced Drug Delivery Systems: A prominent trend is the development of advanced drug delivery systems, such as extended-release tablets and topical gels. These innovations aim to improve patient compliance by reducing dosing frequency and minimizing systemic side effects, particularly gastrointestinal issues. This provides a more convenient and safer treatment option for long-term management of chronic conditions like arthritis.
• Non-Opioid Pain Management: A key trend is the positioning of meloxicam as a primary non-opioid alternative for acute and post-operative pain. New fast-acting formulations, including intravenous injections, are being developed and approved to provide effective pain relief without the risks of addiction and side effects associated with opioids. This trend directly addresses the global opioid crisis.
• Growth of Generic Formulations: The market continues to be shaped by the increasing prevalence of generic meloxicam. Following the patent expiration of branded products, numerous manufacturers have introduced low-cost alternatives. This trend has intensified price competition, making meloxicam more accessible to a wider patient population and expanding its market share, especially in developing economies.
• Combination Therapies: Another emerging trend is the research and development of combination therapies involving meloxicam. This involves combining meloxicam with other active ingredients to target multiple aspects of pain and inflammation simultaneously. Such strategies aim to improve therapeutic outcomes and offer a more comprehensive treatment approach, particularly for complex inflammatory conditions.
• Expansion into Veterinary Medicine: A notable trend is the growing application of meloxicam in veterinary medicine. As a safe and effective non-steroidal anti-inflammatory drug (NSAID) for animals, meloxicam is increasingly used to manage pain and inflammation in companion animals and livestock. This application presents a new growth avenue for the market, driven by the increasing focus on animal health.

These trends are fundamentally reshaping the meloxicam market by expanding its applications beyond traditional arthritis treatment, offering safer and more convenient formulations, and increasing accessibility through generic competition. The market is moving towards more specialized, application-specific products that cater to the evolving needs of both human and veterinary healthcare.

Recent Developments in the Meloxicam Market

The meloxicam market has seen a number of key developments driven by innovations in drug delivery and a strong focus on patient safety and convenience. These advancements are aimed at addressing evolving healthcare needs, particularly in chronic pain management and post-operative care, and are impacting the competitive landscape and product offerings globally.

• Fast-Acting IV Formulation: A significant development is the approval and market availability of a new intravenous (IV) formulation of meloxicam for moderate-to-severe acute pain. This fast-acting non-opioid injectable offers a crucial alternative for post-surgical pain management, helping to reduce reliance on opioids. Its introduction is particularly impactful in hospital settings, where a rapid onset of action is essential.
• Extended-Release Tablets: Another key development is the introduction of extended-release meloxicam tablets. These formulations are designed to provide sustained pain relief over a 24-hour period with a single daily dose. This improves patient adherence, reduces dosing frequency, and helps to minimize the risk of gastrointestinal side effects, making it a more convenient option for long-term management of chronic arthritis.
• Growing Generic Competition: The market has experienced a surge in generic competition following the expiration of key patents. This development has led to a reduction in the average price of meloxicam, making it more affordable and accessible to a wider patient population. While this puts pressure on the pricing of branded products, it also drives market volume and expands the drug's overall use.
• Topical Gels for Localized Pain: The development and introduction of topical meloxicam gels represent a significant advancement for treating localized pain. These gels allow for direct application to the affected area, providing targeted relief while reducing systemic exposure and the associated side effects. This formulation is particularly beneficial for patients with conditions like osteoarthritis in specific joints.
• Strategic Partnerships and Acquisitions: Pharmaceutical companies are engaging in strategic partnerships and acquisitions to expand their meloxicam product portfolios and geographical reach. These collaborations, particularly with generic manufacturers and companies specializing in new drug delivery technologies, are accelerating market growth, fostering innovation, and helping companies to gain a competitive edge.

These developments are having a profound impact on the meloxicam market by diversifying product offerings, enhancing patient safety and convenience, and increasing market accessibility. The market is shifting from a reliance on traditional oral tablets to a more diverse range of formulations that cater to specific patient needs, from acute post-operative pain to chronic arthritis management.

Strategic Growth Opportunities in the Meloxicam Market

The meloxicam market offers several strategic growth opportunities, driven by its versatile applications and the increasing demand for effective, non-opioid pain management solutions. These opportunities are focused on expanding into new therapeutic areas, developing innovative formulations, and catering to specific patient populations, thereby enhancing market penetration and value.

• Post-Operative Pain Management: A significant growth opportunity lies in positioning meloxicam as a first-line non-opioid alternative for post-operative pain. The development of fast-acting intravenous formulations allows for immediate pain relief in a clinical setting, reducing the need for addictive opioids. This is a high-growth area, driven by global efforts to mitigate the opioid crisis.
• Topical Formulations for Arthritis: The growing demand for non-systemic treatments for localized pain presents a key opportunity for topical meloxicam gels and creams. These formulations can provide targeted relief for conditions like osteoarthritis, minimizing the risk of systemic side effects. This application addresses a large patient population seeking a safer alternative to oral NSAIDs.
• Combination Therapies for Chronic Pain: Developing meloxicam-based combination therapies offers a strategic opportunity to create more potent and comprehensive pain management solutions. By combining meloxicam with other analgesics or anti-inflammatory agents, companies can offer multi-modal pain relief, which is particularly effective for managing chronic conditions that do not respond to a single medication.
• Veterinary Applications: The veterinary pharmaceutical sector represents a promising growth opportunity for meloxicam. As pet ownership and animal healthcare expenditure rise, there is increasing demand for effective and safe pain and inflammation management in animals. Meloxicam's established efficacy makes it a strong candidate for this expanding market segment.
• Formulations for Pediatrics: A niche but important opportunity exists in developing pediatric-specific meloxicam formulations. With the approval of meloxicam for juvenile rheumatoid arthritis, there is a need for child-friendly dosage forms, such as suspensions or chewable tablets. This would address a significant unmet need and expand the drug's market to a younger patient population.

These growth opportunities are impacting the meloxicam market by driving innovation beyond its traditional use. By focusing on these strategic areas, companies can differentiate their products, capture new market segments, and ultimately solidify meloxicam's position as a versatile and essential non-opioid medication in a wide range of applications.

Meloxicam Market Driver and Challenges

The meloxicam market is a dynamic landscape shaped by various drivers that propel its growth and a set of challenges that can hinder its progress. The key drivers are rooted in global demographic shifts and the pressing need for safer pain management, while challenges arise from regulatory scrutiny and intense market competition.

The factors responsible for driving the meloxicam market include:

1. Rising Prevalence of Arthritis: The increasing global prevalence of osteoarthritis and rheumatoid arthritis, particularly among the aging population, is a primary driver. Meloxicam is a widely prescribed NSAID for these conditions, and as the number of patients grows, so does the demand for the drug. This demographic shift provides a solid foundation for market expansion.

2. Preference for Non-Opioid Pain Relief: A major driver is the global effort to combat the opioid crisis. Healthcare providers and patients are increasingly seeking effective non-opioid alternatives for both chronic and acute pain management. Meloxicam, with its established efficacy and favorable safety profile compared to opioids, is well-positioned to meet this demand.

3. Patent Expirations and Generic Growth: The expiration of key patents has led to a proliferation of generic meloxicam products. This has made the drug more affordable and accessible, particularly in emerging markets. The resulting increase in market volume and competition is a significant driver of overall market growth.

4. Technological Advancements: Innovations in drug delivery systems, such as extended-release and intravenous formulations, are driving market growth. These advancements improve patient convenience, efficacy, and safety, making meloxicam a more attractive option for a wider range of applications, including post-operative care.

5. Growing Healthcare Expenditure: The rise in global healthcare expenditure, particularly in emerging economies, is a key driver. Increased spending allows for better access to medications and advanced treatments, thereby boosting the demand for meloxicam and other anti-inflammatory drugs.

Challenges in the meloxicam market are:

1. Side Effect Profile: Meloxicam, like all NSAIDs, carries a risk of side effects, including gastrointestinal and cardiovascular issues. These safety concerns can limit its use in certain patient populations and necessitate careful monitoring, which poses a significant challenge to market growth.

2. Competition from Alternatives: The market is highly competitive, not only from generic versions of meloxicam but also from other NSAIDs, biologics, and novel pain therapies. Differentiating meloxicam and its new formulations in a crowded market and maintaining market share is a continuous challenge for manufacturers.

3. Strict Regulatory Environment: The development and approval of new meloxicam formulations face a stringent regulatory environment. Regulatory bodies require extensive clinical data to prove efficacy and safety, which can be a costly and time-consuming process. This creates a barrier to entry for new products and slows down innovation.

The meloxicam market is being propelled by the growing need for effective, safe, and affordable pain management solutions, driven by an aging population and the fight against the opioid crisis. However, these positive trends are tempered by the inherent safety concerns associated with NSAIDs, intense market competition, and the challenging regulatory landscape that new formulations must navigate to reach the market.

List of Meloxicam Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies meloxicam companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the meloxicam companies profiled in this report include-

• Boehringer Ingelheim
• Baudax
• Perrigo
• Recro Pharma
• Iroko Pharma
• Zyla Life Sciences
• Axsome Therapeutics
• Orbis Biosciences
• Cellix Bio
• Ligand Pharma

Meloxicam Market by Segment

The study includes a forecast for the global meloxicam market by type, application, and region.

Meloxicam Market by Type [Value from 2019 to 2031]:

• by Ingredient
• by Route
• by Dosage Form

Meloxicam Market by Application [Value from 2019 to 2031]:

• Rheumatoid Arthritis
• Osteoarthritis
• Soft Tissue Inflammation
• Traumatic Pain
• Post-Operative Pain
• Others

Country Wise Outlook for the Meloxicam Market

The meloxicam market is undergoing significant transformations, driven by a growing aging population and rising prevalence of chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis. This has spurred a shift towards new formulations and a greater emphasis on non-opioid pain management. The market is also heavily influenced by generic competition and regional regulatory dynamics, shaping pricing and market access globally.

• United States: The U.S. market is highly competitive, with a strong presence of both branded and generic meloxicam. A key development is the focus on new, fast-acting formulations, such as those for intravenous use, aimed at managing moderate-to-severe acute pain. These innovations offer a non-opioid alternative for post-operative care, addressing the national opioid crisis and meeting demand for safer pain management.
• China: The Chinese meloxicam market is experiencing rapid growth, fueled by the country's expanding healthcare infrastructure and a large, aging population. Local and international companies are increasing their presence, with a focus on producing and distributing cost-effective generic versions. This expansion is supported by government initiatives to improve healthcare access and manage the rising burden of chronic diseases.
• Germany: Germany represents a mature European market for meloxicam, characterized by a well-established healthcare system and a strong emphasis on quality and safety. The market is driven by the management of chronic conditions, with a steady demand for both oral and injectable formulations. Regulatory standards and reimbursement policies play a crucial role in shaping market dynamics and product availability.
• India: India is a fast-growing market, primarily dominated by generic meloxicam products due to their affordability. The market is propelled by a large patient base with inflammatory conditions and a growing middle class with increasing access to healthcare. Pharmaceutical companies are focusing on low-cost manufacturing and expanding their distribution networks to cater to this high-demand, price-sensitive market.
• Japan: The Japanese market is defined by its focus on technological advancements and high-quality pharmaceutical products. While the market for meloxicam is steady, there is a strong emphasis on developing and utilizing advanced drug delivery systems and formulations to improve efficacy and reduce side effects. This reflects Japan's patient-centric approach to healthcare and its advanced geriatric care needs.

Features of the Global Meloxicam Market

• Market Size Estimates: Meloxicam market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Meloxicam market size by type, application, and region in terms of value ($B).
• Regional Analysis: Meloxicam market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the meloxicam market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the meloxicam market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the meloxicam market by type (by ingredient, by route, and by dosage form), application (rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, post-operative pain, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Meloxicam Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 by Ingredient: Trends and Forecast (2019-2031)
• 4.4 by Route: Trends and Forecast (2019-2031)
• 4.5 by Dosage Form: Trends and Forecast (2019-2031)

5. Global Meloxicam Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Rheumatoid Arthritis: Trends and Forecast (2019-2031)
• 5.4 Osteoarthritis: Trends and Forecast (2019-2031)
• 5.5 Soft Tissue Inflammation: Trends and Forecast (2019-2031)
• 5.6 Traumatic Pain: Trends and Forecast (2019-2031)
• 5.7 Post-Operative Pain: Trends and Forecast (2019-2031)
• 5.8 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Meloxicam Market by Region

7. North American Meloxicam Market

• 7.1 Overview
• 7.2 North American Meloxicam Market by Type
• 7.3 North American Meloxicam Market by Application
• 7.4 United States Meloxicam Market
• 7.5 Mexican Meloxicam Market
• 7.6 Canadian Meloxicam Market

8. European Meloxicam Market

• 8.1 Overview
• 8.2 European Meloxicam Market by Type
• 8.3 European Meloxicam Market by Application
• 8.4 German Meloxicam Market
• 8.5 French Meloxicam Market
• 8.6 Spanish Meloxicam Market
• 8.7 Italian Meloxicam Market
• 8.8 United Kingdom Meloxicam Market

9. APAC Meloxicam Market

• 9.1 Overview
• 9.2 APAC Meloxicam Market by Type
• 9.3 APAC Meloxicam Market by Application
• 9.4 Japanese Meloxicam Market
• 9.5 Indian Meloxicam Market
• 9.6 Chinese Meloxicam Market
• 9.7 South Korean Meloxicam Market
• 9.8 Indonesian Meloxicam Market

10. ROW Meloxicam Market

• 10.1 Overview
• 10.2 ROW Meloxicam Market by Type
• 10.3 ROW Meloxicam Market by Application
• 10.4 Middle Eastern Meloxicam Market
• 10.5 South American Meloxicam Market
• 10.6 African Meloxicam Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Meloxicam Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Boehringer Ingelheim
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Baudax
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Perrigo
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Recro Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Iroko Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Zyla Life Sciences
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Axsome Therapeutics
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Orbis Biosciences
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Cellix Bio
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Ligand Pharma
  • Company Overview
  • Meloxicam Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us

List of Figures

• Figure 1.1: Trends and Forecast for the Global Meloxicam Market
• Figure 2.1: Usage of Meloxicam Market
• Figure 2.2: Classification of the Global Meloxicam Market
• Figure 2.3: Supply Chain of the Global Meloxicam Market
• Figure 3.1: Driver and Challenges of the Meloxicam Market
• Figure 3.2: PESTLE Analysis
• Figure 3.3: Patent Analysis
• Figure 3.4: Regulatory Environment
• Figure 4.1: Global Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Meloxicam Market ($B) by Type
• Figure 4.3: Forecast for the Global Meloxicam Market ($B) by Type
• Figure 4.4: Trends and Forecast for by Ingredient in the Global Meloxicam Market (2019-2031)
• Figure 4.5: Trends and Forecast for by Route in the Global Meloxicam Market (2019-2031)
• Figure 4.6: Trends and Forecast for by Dosage Form in the Global Meloxicam Market (2019-2031)
• Figure 5.1: Global Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Meloxicam Market ($B) by Application
• Figure 5.3: Forecast for the Global Meloxicam Market ($B) by Application
• Figure 5.4: Trends and Forecast for Rheumatoid Arthritis in the Global Meloxicam Market (2019-2031)
• Figure 5.5: Trends and Forecast for Osteoarthritis in the Global Meloxicam Market (2019-2031)
• Figure 5.6: Trends and Forecast for Soft Tissue Inflammation in the Global Meloxicam Market (2019-2031)
• Figure 5.7: Trends and Forecast for Traumatic Pain in the Global Meloxicam Market (2019-2031)
• Figure 5.8: Trends and Forecast for Post-Operative Pain in the Global Meloxicam Market (2019-2031)
• Figure 5.9: Trends and Forecast for Others in the Global Meloxicam Market (2019-2031)
• Figure 6.1: Trends of the Global Meloxicam Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Meloxicam Market ($B) by Region (2025-2031)
• Figure 7.1: North American Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 7.2: Trends of the North American Meloxicam Market ($B) by Type (2019-2024)
• Figure 7.3: Forecast for the North American Meloxicam Market ($B) by Type (2025-2031)
• Figure 7.4: North American Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 7.5: Trends of the North American Meloxicam Market ($B) by Application (2019-2024)
• Figure 7.6: Forecast for the North American Meloxicam Market ($B) by Application (2025-2031)
• Figure 7.7: Trends and Forecast for the United States Meloxicam Market ($B) (2019-2031)
• Figure 7.8: Trends and Forecast for the Mexican Meloxicam Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Canadian Meloxicam Market ($B) (2019-2031)
• Figure 8.1: European Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 8.2: Trends of the European Meloxicam Market ($B) by Type (2019-2024)
• Figure 8.3: Forecast for the European Meloxicam Market ($B) by Type (2025-2031)
• Figure 8.4: European Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 8.5: Trends of the European Meloxicam Market ($B) by Application (2019-2024)
• Figure 8.6: Forecast for the European Meloxicam Market ($B) by Application (2025-2031)
• Figure 8.7: Trends and Forecast for the German Meloxicam Market ($B) (2019-2031)
• Figure 8.8: Trends and Forecast for the French Meloxicam Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the Spanish Meloxicam Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Italian Meloxicam Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the United Kingdom Meloxicam Market ($B) (2019-2031)
• Figure 9.1: APAC Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 9.2: Trends of the APAC Meloxicam Market ($B) by Type (2019-2024)
• Figure 9.3: Forecast for the APAC Meloxicam Market ($B) by Type (2025-2031)
• Figure 9.4: APAC Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 9.5: Trends of the APAC Meloxicam Market ($B) by Application (2019-2024)
• Figure 9.6: Forecast for the APAC Meloxicam Market ($B) by Application (2025-2031)
• Figure 9.7: Trends and Forecast for the Japanese Meloxicam Market ($B) (2019-2031)
• Figure 9.8: Trends and Forecast for the Indian Meloxicam Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Chinese Meloxicam Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the South Korean Meloxicam Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the Indonesian Meloxicam Market ($B) (2019-2031)
• Figure 10.1: ROW Meloxicam Market by Type in 2019, 2024, and 2031
• Figure 10.2: Trends of the ROW Meloxicam Market ($B) by Type (2019-2024)
• Figure 10.3: Forecast for the ROW Meloxicam Market ($B) by Type (2025-2031)
• Figure 10.4: ROW Meloxicam Market by Application in 2019, 2024, and 2031
• Figure 10.5: Trends of the ROW Meloxicam Market ($B) by Application (2019-2024)
• Figure 10.6: Forecast for the ROW Meloxicam Market ($B) by Application (2025-2031)
• Figure 10.7: Trends and Forecast for the Middle Eastern Meloxicam Market ($B) (2019-2031)
• Figure 10.8: Trends and Forecast for the South American Meloxicam Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the African Meloxicam Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Meloxicam Market
• Figure 11.2: Market Share (%) of Top Players in the Global Meloxicam Market (2024)
• Figure 12.1: Growth Opportunities for the Global Meloxicam Market by Type
• Figure 12.2: Growth Opportunities for the Global Meloxicam Market by Application
• Figure 12.3: Growth Opportunities for the Global Meloxicam Market by Region
• Figure 12.4: Emerging Trends in the Global Meloxicam Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Meloxicam Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Meloxicam Market by Region
• Table 1.3: Global Meloxicam Market Parameters and Attributes
• Table 3.1: Trends of the Global Meloxicam Market (2019-2024)
• Table 3.2: Forecast for the Global Meloxicam Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Meloxicam Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Meloxicam Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Meloxicam Market (2025-2031)
• Table 4.4: Trends of by Ingredient in the Global Meloxicam Market (2019-2024)
• Table 4.5: Forecast for by Ingredient in the Global Meloxicam Market (2025-2031)
• Table 4.6: Trends of by Route in the Global Meloxicam Market (2019-2024)
• Table 4.7: Forecast for by Route in the Global Meloxicam Market (2025-2031)
• Table 4.8: Trends of by Dosage Form in the Global Meloxicam Market (2019-2024)
• Table 4.9: Forecast for by Dosage Form in the Global Meloxicam Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Meloxicam Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Meloxicam Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Meloxicam Market (2025-2031)
• Table 5.4: Trends of Rheumatoid Arthritis in the Global Meloxicam Market (2019-2024)
• Table 5.5: Forecast for Rheumatoid Arthritis in the Global Meloxicam Market (2025-2031)
• Table 5.6: Trends of Osteoarthritis in the Global Meloxicam Market (2019-2024)
• Table 5.7: Forecast for Osteoarthritis in the Global Meloxicam Market (2025-2031)
• Table 5.8: Trends of Soft Tissue Inflammation in the Global Meloxicam Market (2019-2024)
• Table 5.9: Forecast for Soft Tissue Inflammation in the Global Meloxicam Market (2025-2031)
• Table 5.10: Trends of Traumatic Pain in the Global Meloxicam Market (2019-2024)
• Table 5.11: Forecast for Traumatic Pain in the Global Meloxicam Market (2025-2031)
• Table 5.12: Trends of Post-Operative Pain in the Global Meloxicam Market (2019-2024)
• Table 5.13: Forecast for Post-Operative Pain in the Global Meloxicam Market (2025-2031)
• Table 5.14: Trends of Others in the Global Meloxicam Market (2019-2024)
• Table 5.15: Forecast for Others in the Global Meloxicam Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Meloxicam Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Meloxicam Market (2025-2031)
• Table 7.1: Trends of the North American Meloxicam Market (2019-2024)
• Table 7.2: Forecast for the North American Meloxicam Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Type in the North American Meloxicam Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Type in the North American Meloxicam Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various Application in the North American Meloxicam Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various Application in the North American Meloxicam Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Meloxicam Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Meloxicam Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Meloxicam Market (2019-2031)
• Table 8.1: Trends of the European Meloxicam Market (2019-2024)
• Table 8.2: Forecast for the European Meloxicam Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Type in the European Meloxicam Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Type in the European Meloxicam Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various Application in the European Meloxicam Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various Application in the European Meloxicam Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Meloxicam Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Meloxicam Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Meloxicam Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Meloxicam Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Meloxicam Market (2019-2031)
• Table 9.1: Trends of the APAC Meloxicam Market (2019-2024)
• Table 9.2: Forecast for the APAC Meloxicam Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Meloxicam Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Meloxicam Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Meloxicam Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Meloxicam Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Meloxicam Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Meloxicam Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Meloxicam Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Meloxicam Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Meloxicam Market (2019-2031)
• Table 10.1: Trends of the ROW Meloxicam Market (2019-2024)
• Table 10.2: Forecast for the ROW Meloxicam Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Meloxicam Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Meloxicam Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Meloxicam Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Meloxicam Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Meloxicam Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Meloxicam Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Meloxicam Market (2019-2031)
• Table 11.1: Product Mapping of Meloxicam Suppliers Based on Segments
• Table 11.2: Operational Integration of Meloxicam Manufacturers
• Table 11.3: Rankings of Suppliers Based on Meloxicam Revenue
• Table 12.1: New Product Launches by Major Meloxicam Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Meloxicam Market